Loading
PB
Prometheus Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Cormorant Asset Management, LP, was filed 18 Mar 2021.
Prometheus Biosciences, Inc.: what insiders have been doing
Prometheus Biosciences, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Prometheus Biosciences, Inc. The previous disclosure was published on 16 June 2023.
Over the whole record (from 2021), the tally stands at 7 purchases and 12 sales.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
74
Thresholds
n/a
Buy Volume
€45M
7 ops. · all time
Sell Volume
€111M
12 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$5.9M
Net income-US$122M-2081.8% margin
Last declaration on 16 June 2023
Declarations74 total
14,000 sharesCommon StockSEC:0000899243-23-015761:1
10,000 sharesCommon StockSEC:0000899243-23-015759:1
12,754 sharesCommon StockSEC:0000899243-23-015761:0
2,071 sharesCommon StockSEC:0000899243-23-015755:0
7,278 sharesCommon StockSEC:0000899243-23-015759:0
2,674 sharesCommon StockSEC:0000899243-23-015753:0
2,123 sharesCommon StockSEC:0000899243-23-015758:0
178,098 sharesCommon StockSEC:0000899243-23-015760:0
2,071 sharesCommon StockSEC:0000899243-23-015757:0
2,071 sharesCommon StockSEC:0000899243-23-015762:0
87,973 sharesCommon StockSEC:0000899243-23-015754:0
2,071 sharesCommon StockSEC:0000899243-23-015756:0
3 shares@ US$1.700.0% of flowCommon StockSEC:0001209191-23-034050:1
14,000 shares0Common StockSEC:0001209191-23-034013:1
10,000 shares0Common StockSEC:0001209191-23-034004:1
78,162 shares@ US$3.1068.6% of flowCommon StockSEC:0001209191-23-034038:0
122,528 shares@ US$2.9057.5% of flowCommon StockSEC:0001209191-23-034050:0
14,000 shares0Common StockSEC:0001209191-23-034013:0
10,000 shares0Common StockSEC:0001209191-23-034004:0
2,174 shares0Common StockSEC:0001209191-23-031170:0
2,071 shares0Common StockSEC:0001209191-23-031184:0
2,123 shares0Common StockSEC:0001209191-23-031175:0
2,278 shares0Common StockSEC:0001209191-23-031188:0
2,071 shares0Common StockSEC:0001209191-23-031180:0
2,071 shares0Common StockSEC:0001209191-23-031191:0
25 of 74 declarations
About Prometheus Biosciences, Inc.
Prometheus Biosciences, Inc. was a U.S.-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutic and companion diagnostic products for immune-mediated diseases. Before its acquisition, the company was listed in the United States on the NASDAQ market under the ticker RXDX and was headquartered in San Diego, California, a major biotechnology hub. Its model centered on precision medicine: using biomarker-driven patient stratification and targeted clinical development to improve the odds of therapeutic success in complex inflammatory and autoimmune disorders.
Founded in 2016, Prometheus built its reputation around inflammatory bowel disease and broader immunology applications. Its lead asset was PRA023, a monoclonal antibody program aimed at ulcerative colitis, Crohn’s disease, and other immune-mediated conditions. The company’s strategy was not simply to develop a drug candidate, but to combine drug development with a companion diagnostic and a proprietary data-driven approach. That positioning made Prometheus stand out as a precision immunology platform rather than a conventional single-asset biotech, which is an important distinction for institutional investors assessing both upside potential and execution risk.
Read moreShow less
From a competitive standpoint, Prometheus operated in a crowded and scientifically demanding field. Large pharmaceutical companies, specialty biotechs, and diagnostics players are all competing in immunology and inflammatory disease. Prometheus’ differentiator was its precision medicine framework and its effort to connect patient biology more directly to treatment selection. In theory, that approach could support better clinical outcomes, stronger differentiation, and potentially more efficient commercialization. In practice, however, it also meant the company carried the typical biotech risks: clinical trial uncertainty, regulatory hurdles, manufacturing complexity, and intense competition from alternative mechanisms of action.
The most important recent development in the company’s history was Merck’s acquisition. In April 2023, Merck announced a definitive agreement to acquire Prometheus Biosciences, and the transaction was completed in June 2023. Merck described the deal as a way to expand its immunology franchise and add Prometheus’ precision-medicine capabilities and late-stage pipeline to its portfolio. The acquisition, valued at roughly $10.8 billion, effectively ended Prometheus’ life as an independent public company. As a result, for investors reviewing SEC Form 4 insider activity or legacy market data, it is important to note that Prometheus Biosciences no longer trades independently on NASDAQ in the United States; its assets were absorbed into Merck.
For French-speaking investors, Prometheus remains a useful case study in how a focused clinical-stage biotech can create strategic value through a differentiated platform, strong scientific positioning, and acquisition appeal in a consolidating immunology market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
